Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

4.55 0.44

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.32

Max

4.63

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	2.2M -35M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+68.36% upside

Dividendes
By Acuity
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	62M 357M
Ouverture précédente	4.11
Clôture précédente	4.55

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 juil. 2026, 23:56 UTC

eBay Inc. shares are trading lower in after-market hours, with no specific company news identified. The stock remains near the midpoint of its one-month trading range.

27 juil. 2026, 23:56 UTC

Steel Dynamics Inc shares are trading lower in after-market hours. No specific company news was identified to explain the price movement.

27 juil. 2026, 23:56 UTC

Alibaba Group Holding Ltd shows a slight gain in after-market trading, reflecting positive market sentiment. The stock remains above its 20-day moving average.

27 juil. 2026, 23:56 UTC

PepsiCo Inc. shares remained roughly flat during after-market hours, trading within a narrow range around the middle of their one-month range.

27 juil. 2026, 23:56 UTC

Monday.Com Ltd. shares are lower in after-market trading, fluctuating within a narrow range without specific news driving the decline.

27 juil. 2026, 23:56 UTC

Correlated Moves

Kulicke and Soffa Industries shares declined in after-market trading, reflecting broader weakness in the semiconductor sector and a drop in the Nasdaq 100 Index.

27 juil. 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

27 juil. 2026, 23:56 UTC

Correlated Moves

News

Diamondback Energy gained during after-market hours, buoyed by strong revenue growth and a favorable market position, with shares peaking above Monday's close.

27 juil. 2026, 23:56 UTC

Under Armour Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

27 juil. 2026, 23:56 UTC

Whirlpool Corp shares are higher in after-market hours, reflecting a modest increase since Monday's close amid positive sentiment in European markets.

27 juil. 2026, 23:56 UTC

Archer-Daniels-Midland Co is rising in after-market trading, reversing three sessions of declines. No specific news was identified to explain this movement.

27 juil. 2026, 23:56 UTC

Matador Resources Co shares are higher in after-market trading following Monday's close, despite remaining below their 20-day moving average.

27 juil. 2026, 23:56 UTC

JD.Com Inc. shares declined in after-market trading, despite a strong one-month gain and trading above its 20-day moving average. No specific news was identified.

27 juil. 2026, 23:56 UTC

Correlated Moves

Costco shares are lower in after-market trading, following a slight decline in the Nasdaq 100 Index. The stock remains above its 20-day moving average.

27 juil. 2026, 23:56 UTC

Social Media

General Motors plans a $6 billion investment in U.S. manufacturing, including an expansion at its Orion Township plant. Shares are roughly flat in after-market trading.

27 juil. 2026, 23:56 UTC

Shell PLC shares showed little change in after-market trading. The stock remains above its 20-day moving average amid positive sentiment in European markets.

27 juil. 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

27 juil. 2026, 23:56 UTC

Trimble Inc shares are lower in after-market hours following Monday's close. The stock remains above its 20-day moving average despite the decline.

27 juil. 2026, 23:52 UTC

Mexico's Business Confidence Data Release on August 3, 2026, Expected to Reflect Cautious Sentiment Amid Global Market Volatility and Inflationary Pressures.

27 juil. 2026, 23:52 UTC

U.S. Initial Jobless Claims Expected at 204,000 Amid Positive Labor Market Sentiment and Fed Policy Speculation

27 juil. 2026, 23:52 UTC

Australia's Building Permits Expected to Decline by 0.5% in June Amidst Ongoing Weakness in Housing Construction and Elevated Borrowing Costs

27 juil. 2026, 23:52 UTC

Weis Markets shares declined after-market, remaining about 4.47% below their 20-day moving average. No specific news was identified to explain the movement.

27 juil. 2026, 23:52 UTC

Xylem Inc shares are higher in after-market trading, continuing a trend of four consecutive sessions of gains and remaining above the 20-day moving average.

27 juil. 2026, 23:51 UTC

Trustmark Corp shares are higher during after-market hours, moving from a low of -0.04% to a high of 0.95% since Monday's close.

27 juil. 2026, 23:51 UTC

Correlated Moves

Vanguard Total Bond Market ETF trades higher after-market, reflecting broader market trends amid easing geopolitical tensions and a drop in oil prices.

27 juil. 2026, 23:51 UTC

J B Hunt Transport Services Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the movement.

27 juil. 2026, 23:51 UTC

Social Media

Correlated Moves

Shares lower in after-market trading; call writer profits $1.28 million.

27 juil. 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

27 juil. 2026, 23:51 UTC

News

Event

UDR Inc reported second-quarter net income of $69.035 million. Shares declined in after-market trading amid concerns over flat revenue and rising costs.

27 juil. 2026, 23:51 UTC

News

L3Harris Technologies has secured Pentagon agreements to boost missile defense production, but shares are trading lower in after-market hours.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

68.36% hausse

Prévisions sur 12 Mois

Moyen 7.29 USD 68.36%

Haut 11 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.